Article thumbnail

Beta1-Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation

By Amir M. Nia, Evren Caglayan, Natig Gassanov, Tom Zimmermann, Orhan Aslan, Martin Hellmich, Firat Duru, Erland Erdmann, Stephan Rosenkranz and Fikret Er
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor.
  2. (2006). A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
  3. (2003). Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction.
  4. (2004). Association between hypertension and the alpha-adducin, beta1-adrenoreceptor, and G-protein beta3 subunit genes in the Japanese population; the Suita study.
  5. (2002). Atrial fibrillation: strategies to control, combat, and cure.
  6. (2007). Atrial fibrosis and the mechanisms of atrial fibrillation.
  7. (2009). Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases.
  8. (2003). Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure.
  9. (1997). Beta-adrenergic augmentation of flecainide-induced conduction slowing in canine Purkinje fibers.
  10. (1989). Beta-adrenergic inhibition of cardiac sodium channels by dual G-protein pathways.
  11. (1999). Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy.
  12. (1999). Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay.
  13. (1986). Drug therapy.
  14. (2010). Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. Clin Res Cardiol.
  15. (2004). Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R.Ga n d4
  16. (2006). guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force
  17. (1990). Inhibition of cardiac Na+ currents by isoproterenol.
  18. (1963). Isolation and analysis of the deoxyribonucleic acid of Mycoplasma mycoides var.
  19. (1989). Isoproterenol, DBcAMP, and forskolin inhibit cardiac sodium current.
  20. (1960). Key position of catecholamines in functional and degenerative cardiovascular pathology.
  21. (2004). Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.
  22. (1993). Mechanism of cAMP-dependent modulation of cardiac sodium channel current kinetics.
  23. (2002). Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation.
  24. (2004). Outpatient treatment of recent-onset atrial fibrillation with the ‘‘pill-in-the-pocket’’ approach.
  25. (2007). Plasma catecholamines and ischemic heart disease.
  26. (2001). Polymorphism in the beta(1)-adrenergic receptor gene and hypertension.
  27. (2009). Self-rated health before and after retirement in France (GAZEL): a cohort study.
  28. (2002). Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study.
  29. (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.
  30. (2004). The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines.